Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 7:10 PM
Ignite Modification Date: 2025-12-25 @ 4:45 PM
NCT ID: NCT05794503
Description: None
Frequency Threshold: 0
Time Frame: Up to post operative day 30
Study: NCT05794503
Study Brief: Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine Versus Sugammadex
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Neostigmine One type of Neuromuscular Blockade Reversal Drug Neostigmine: Maintenance neuromuscular blockade with boluses of rocuronium. For reversal, neostigmine. 0 None 0 112 0 112 View
Sugammadex One type of Neuromuscular Blockade Reversal Drug Sugammadex: Maintenance neuromuscular blockade with boluses of rocuronium. For reversal, sugammadex 0 None 0 118 0 118 View
Serious Events(If Any):
Other Events(If Any):